Ministry of Health of the Republic of Moldova
National Agency for Public Health

A technique for detecting the presence of the anti-SARS-CoV-2 IgG marker in blood serum

Authors

Spînu Constantin, MD, DHM
Cebotari Svetlana, MD
Isac Maria, MD, PhD
Sajin Octavian, MD, PhD
Spînu Igor, MD, PhD
Iziumov Nina, MD, PhD

Components:

ELISA Kit

Status

Short-term Patent
MD 1524Z 2021.12.31

Objective

To eliminate equivocal results of anti-SARS-CoV-2 testing by the ELISA method

Procedure



Obtain pacient serum

Testing for the presence of anti-SARS-CoV-2 antibodies in serum using the ELISA

Reading the results:
SO/CO < 0.9 - negative
SO/CO = 0.9 → 1.1 - equivocal
SO/CO >1.1 - positive



Solution

The problem solved by the invention is to develop an original method for blood samples testing in ELISA by excluding equivocal results following the processing of samples with a special substance (removal of non-specific inhibitors).

Advantages

Consists in the exclusion of equivocal results, which require repeated investigation of patients after an interval of 2 weeks with additional costs:
collection of samples, transportation, investigation, additional time for repeated investigation of the patient



Repeated testing of the kaolin-treated serum using the ELISA method

Kaolin - $Al_2Si_2O_5(OH)_4$





The result is that there are no more equivocal samples, as they have determined their status